Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

Alan Anderson, Fuad El Rassi, Michael R. DeBaun, Modupe Idowu, Julie Kanter, Soheir Adam, Susanna Curtis, Darla Liles, Biree Andemariam, Morgan L. McLemore, Robert Sheppard Nickel, Poornima Ramadas, Jincy Paulose, Dramane I Laine, Mahmudul Khan, Deepika S. Darbari, Arthur L. Burnett

Blood (2022) 140 (Supplement 1): 1636–1638.

https://doi.org/10.1182/blood-2022-157004

Published: 2022

Journal Articles

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Koji Sasaki, Michael Mauro, Moshe Yair Levy, Ehab L. Atallah, Paul B. Koller, Rodrigo Maegawa, Andrea Damon, Julie Kumar, Mahmudul Khan, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 6784–6786.

https://doi.org/10.1182/blood-2022-167044

Published: 2022

Journal Articles

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Francesco Passamonti, MD, Martin Griesshammer, MD, Michele Cavo, MD, Miklos Egyed, MDPhD Prof., Giulia Benevolo, MD, Timothy Devos, MDPhD, Jeannie Callum, MD, Alessandro M. Vannucchi, MD, Serdar Sivgin, MD, Caroline Bensasson, PhD, Mahmudul Khan, PhD, Nadjat Mounedji, MD, Guray Saydam, MD Prof

Blood (2015) 126 (23): 2807.

https://doi.org/10.1182/blood.V126.23.2807.2807

Published: 2015

Journal Articles

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Robert L. Schlossman, MD, Melissa Alsina, MD, Donna M. Weber, M.D., Steven E. Coutre, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael S. Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole S. Paley, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 1970.

https://doi.org/10.1182/blood.V122.21.1970.1970

Published: 2013

Journal Articles

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

Paul G. Richardson, Robert L. Schlossman, Melissa Alsina, Donna M. Weber, Steven E. Coutre, Cristina Gasparetto, Sutapa Mukhopadhyay, Michael S. Ondovik, Mahmudul Khan, Carole S. Paley, Sagar Lonial

Blood (2013) 122 (14): 2331–2337.

https://doi.org/10.1182/blood-2013-01-481325

Published: 2013

Journal Articles

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Giovanni Barosi, MD, Mohan Agarwal, MD, MNAMS, Sonja Zweegman, MD, PhD, Wolfgang Willenbacher, MD, Sima Pakstyte, MD, Reinier Raymakers, MD, PhD, Nathan Cantoni, MD, Ankur Modi, Mahmudul Khan, PhD, Jose Ricardo Perez, MD, Hans Hasselbalch, MD, Jose Pablo Vargas Viveros, MD, Camila C.G. Linardi, MD, PhD, Heinz Gisslinger, MD, Adelmo Henrique Daumas Gabriel, MD, Francesca Palandri, David Lavie, MD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 2844.

https://doi.org/10.1182/blood.V120.21.2844.2844

Published: 2012

Journal Articles

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Melissa Alsina, MD, Donna Weber, MD, Steven E. Coutre, MD, Sagar Lonial, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole Paley, MD, Robert Schlossman, MD

Blood (2012) 120 (21): 1852.

https://doi.org/10.1182/blood.V120.21.1852.1852

Published: 2012

NARROW

Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only